Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

228M-1

Sigma-Aldrich

BG8, LewisY (F3) Mouse Monoclonal Antibody

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352200
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

F3, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (228M-14)
vial of 0.5 mL concentrate (228M-15)
bottle of 1.0 mL predilute (228M-17)
vial of 1.0 mL concentrate (228M-16)
bottle of 7.0 mL predilute (228M-18)

Produttore/marchio commerciale

Cell Marque

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:50

Isotipo

IgM

Controllo

adenocarcinoma of lung

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

cytoplasmic

Informazioni sul gene

human ... F3(2152)

Descrizione generale

Blood group antigens have been examined as potential discriminators between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). Lewisy is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and its ability to distinguish between PACA and EM was first reported by Jordon and colleagues in 1989. Three groups have since reported their results. These studies included 231 cases of PACA and 197 cases of EM. Sensitivity and specificity for PACA were both 93%. Yaziji H et al. reported a sensitivity of nonmesothelial antigens for adenocarcinoma as organ dependent, with BG8 performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. They concluded using logical regression analysis that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from adenocarcinoma from a variety of sources (lung, ovary, breast, stomach).

Qualità


IVD

IVD

IVD

RUO

Linkage

BG8 Positive Control Slides, Product No. 228S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota sulla preparazione

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Controllo


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

N G Ordóñez
The American journal of surgical pathology, 24(4), 598-606 (2000-04-11)
The distinction between malignant pleural mesotheliomas and adenocarcinomas, particularly those originating in the lung, is a difficult diagnostic problem that can be facilitated by the use of immunohistochemical markers. In this study, the immunoreactivity of thyroid transcription factor-1 (TTF-1), E-cadherin
B Davidson et al.
Virchows Archiv : an international journal of pathology, 435(1), 43-49 (1999-08-04)
The detection of malignant cells in pleural, peritoneal, and pericardial fluids of cancer patients marks the presence of metastatic disease and is associated with a grave prognosis. We evaluated five epithelial markers for the detection of cancer cells in 94
Alberto M Marchevsky et al.
Applied immunohistochemistry & molecular morphology : AIMM, 15(2), 140-144 (2007-05-26)
There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for
Nelson G Ordóñez
The American journal of surgical pathology, 27(8), 1031-1051 (2003-07-29)
A large number of immunohistochemical markers that can facilitate the distinction between epithelioid pleural mesotheliomas and pulmonary peripheral adenocarcinomas have recently become available. The aim of this study is to compare the value of these new markers with others that
J E King et al.
Histopathology, 48(3), 223-232 (2006-01-25)
Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.